Pembro + pem-platinum significantly improved survival vs pbo + pem-platinum in patients (pts) with previously untreated, metastatic nonsquamous NSCLC without sensitizing EGFR/ALK alterations, regardless of PD-L1 TPS, in the phase III KEYNOTE-189 study (NCT02578680). 20 Complejo Hospitalario Universitario Insular Materno-infantil De Gran Canaria, Universidad de Las Palmas de Gran Canaria, 35016 - Las Palmas de Gran Canaria/ES.19 Biostatistics And Research Decision Sciences, Merck & Co., Inc., Rahway/US.18 Global Clinical Development, Merck & Co., Inc., Rahway/US.17 Department Of Thoracic Oncology, Moffitt Cancer Center, 33612 - Tampa/US.16 Department Of Thoracic Oncology, Kansai Medical University Hospital, 573-1010 - Osaka/JP.15 Department Of Medicine, David Geffen School of Medicine at UCLA, 90404 - Los Angeles/US.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |